


Cantor Fitzgerald decreased their target price on RAPT Therapeutics from $71.00 to $58.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 16th. They set an “overweight” rating and a $61.00 target price on the stock. started coverage on RAPT Therapeutics in a research report on Thursday, December 9th. will post -2.67 EPS for the current year.Ī number of research analysts have recently issued reports on RAPT shares. On average, equities analysts expect that RAPT Therapeutics, Inc. The company had revenue of $0.97 million during the quarter, compared to analyst estimates of $1.45 million. RAPT Therapeutics had a negative return on equity of 41.61% and a negative net margin of 1,468.46%. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). RAPT Therapeutics (NASDAQ:RAPT) last issued its earnings results on Wednesday, November 10th. The stock has a fifty day simple moving average of $34.14 and a two-hundred day simple moving average of $33.39. The company has a market capitalization of $874.56 million, a PE ratio of -12.13 and a beta of 0.15.

Shares of RAPT opened at $29.60 on Friday. The shares were sold at an average price of $32.26, for a total value of $96,780.00. On Friday, December 3rd, William Ho sold 3,000 shares of RAPT Therapeutics stock.

The shares were sold at an average price of $40.00, for a total value of $80,000.00.
